Sameek Roychowdhury: Clinical Trials

4 trials sponsored by Sameek Roychowdhury, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 withdrawn. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Recruiting 1, Withdrawn 1

Follow Sameek Roychowdhury: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging - Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2RecruitingSameek Roychowdhury402025-08-262026-02-17
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
Infigratinib - Advanced Malignant Solid Neoplasm, Cholangiocarcinoma
Phase 2CompletedSameek Roychowdhury172020-01-162026-02-24
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression
Phase 2WithdrawnSameek Roychowdhury2019-03-202022-02-18
Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
ponatinib hydrochloride, laboratory biomarker analysis - Malignant Neoplasm
Phase 2CompletedSameek Roychowdhury222015-02-242025-03-24

Conditions studied

Neoplasm Metastasis (2)  ·  Brain Neoplasms (1)  ·  Cholangiocarcinoma (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Piebaldism (1)

Interventions

Magnetic Resonance Spectroscopy (1)  ·  Postmortem Imaging (1)  ·  Tomography, Optical Coherence (1)  ·  brigatinib (1)  ·  infigratinib (1)  ·  pemigatinib (1)  ·  ponatinib (1)

Countries

United States (4)

NIH funding

P30CA016058 (1)